Tag: Cancer: Prostate
2014 to 2021 Saw Increase in Use of Active Surveillance for Low-Risk Prostate Cancer
Considerable variation observed in active surveillance use, from 4.0 to 78.0 percent at practice level and from 0 to 100 percent at practitioner level
Nine Novel Prostate Cancer Variants Identified in Men With African Ancestry
Multiancestry polygenic risk score can stratify prostate cancer risk and differentiate risk for aggressive disease
Magnitude of Reduction in PSA Level May Indicate Outcomes in Prostate Cancer
Findings seen for men treated with enzalutamide for nonmetastatic castration-resistant prostate cancer
Breast, Cervical, Prostate Cancer Screening Still Lower Than Before Pandemic
Prevalence of colorectal cancer screening remained unchanged with increase in stool testing offsetting decrease in colonoscopy
Rucaparib Efficacious in Metastatic Castration-Resistant Prostate Cancer
Longer duration of imaging-based progression-free survival seen in intent-to-treat population and those with BRCA mutation
Talazoparib + Enzalutamide Beneficial in Metastatic Prostate Cancer
Improvement seen in median imaging-based progression-free survival, regardless of homologous recombination repair status
Plant-Based Diet Linked to Reduced Risk for Prostate Cancer Progression
Men in highest quintile of plant-based dietary index had significantly lower risk for prostate cancer progression and recurrence
Patient-Reported Outcome Measure Developed for Radionuclide Therapy in Prostate Cancer
15-item measure deemed by key stakeholders to be relevant and useful in context of RNT for prostate cancer
Apalutamide Safe for Men With Prostate Cancer on Active Surveillance
Greater number of negative posttreatment biopsies seen among men with higher baseline genomic risk score
MRI-Guided Radiotherapy Bests CT Guidance for Prostate Cancer
Benefits seen for genitourinary and gastrointestinal toxic effects
